Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease.

Neurobiology of aging - 1 Aug 2009

Barabash A, Marcos A, Ancín I, Vázquez-Alvarez B, de Ugarte C, Gil P, Fernández C, Encinas M, López-Ibor J J, Cabranes J A

Abstract excerpt

We have investigated whether the -86 C/T promoter polymorphism in CHRNA7 gene, the signal peptide polymorphism of the alpha1-antichymotripsin (ACT) gene or the APOE genotype are associated with an increased risk of mild cognitive impairment (MCI) or affect the risk of evolution to Alzheimer's disease (AD). We have followed up 89 patients with initial diagnoses of amnestic MCI for 49 months. Patients were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha 1-Antichymotrypsin
Share to alpha7 Nicotinic Acetylcholine Receptor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alzheimer Disease

Share to Apolipoproteins E

Share to Cognition Disorders

Share to Disease Progression

Share to Longitudinal Studies

Share to Receptors, Nicotinic

Source

Identifiers

PMID: 18078695
DOI: 10.1016/j.neurobiolaging.2007.11.003

Genes

CHRNA7
APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease.PMID 18078695Read ↗

Progression from amnesic mild cognitive impairment to Alzheimer's disease: ESR1 and ESR2 polymorphisms and APOE gene.Semantic proximity Read ↗

Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects.Semantic proximity Read ↗

A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease.Semantic proximity Read ↗

Conversion from MCI to AD in patients with the APOE ε4 genotype: Prediction by plasma HCY and serum BDNF.Semantic proximity Read ↗

alpha-1-Antichymotrypsin polymorphism in the gene promoter region affects survival and synapsis loss in Alzheimer's disease.Semantic proximity Read ↗

Epistasis between APOE and nicotinic receptor gene CHRNA4 in age related cognitive function and decline.Semantic proximity Read ↗

[ACT/AA polymorphism could duplicate the APOE*epsilon4-associated Alzheimer's disease risk].Semantic proximity Read ↗

APOE and COMT polymorphisms are complementary biomarkers of status, stability, and transitions in normal aging and early mild cognitive impairmentSemantic proximity Read ↗

Genetic variants in the choline acetyltransferase (ChAT) gene are modestly associated with normal cognitive function in the elderly.Semantic proximity Read ↗

The H1 haplotype of the tau gene (MAPT) is associated with mild cognitive impairment.Semantic proximity Read ↗

Evaluation of choline acetyltransferase gene polymorphism (2384 G/A) in Alzheimer's disease and mild cognitive impairment.Semantic proximity Read ↗

Alpha-1-antichymotrypsin (ACT or SERPINA3) polymorphism may affect age-at-onset and disease duration of Alzheimer's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.